Pharmacological Normalization of Pancreatic Cancer–Associated Fibroblast Secretome Impairs Pro-metastatic Cross-Talk With Macrophages
R. Samain, A. Brunel, T. Douché, M. Fanjul, S. Cassant-Sourdy, J. Rochotte, J. Cros, C. Neuzillet, J. Raffenne, C. Duluc, A. Perraud, J. Nigri, V. Gigoux, I. Bieche, M. Ponzo, G. Carpentier, I. Cascone, R. Tomasini, H.A. Schmid, M. Mathonnet, R. Nicolle, M.P. Bousquet, Y. Martineau, S. Pyronnet, C. Jean, Corinne BousquetCellular and Molecular Gastroenterology and Hepatology2021
Cancer-associated fibroblasts orchestrate pancreatic adeno- carcinoma (PDA) aggressiveness. We show that the Food and Drug Administration–approved somatostatin analog SOM230 inhibits metastasis in murine PDA models by acting through its receptor sst1 to disrupt the cancer-associated fibroblast production of colony stimulating factor 1, a prometastatic and macrophage-attracting chemokine whose stromal expression is associated with PDA aggressiveness.